E
Lineage Cell Therapeutics, Inc.
LCTX
$0.50
-$0.02-3.85%
E
Sell
1/7/2025Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to E+ from D- on 1/7/2025 due to a decline in the total return index and volatility index.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to E+ from D- on 1/7/2025 due to a decline in the total return index and volatility index.
D
Sell
8/15/2024Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D- from E+ on 8/15/2024 due to a noticeable increase in the growth index and valuation index. Earnings per share increased from -$0.0358 to -$0.0305, EBIT increased 11.92% from -$6.66M to -$5.87M, and operating cash flow increased 10.5% from -$5.78M to -$5.18M.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D- from E+ on 8/15/2024 due to a noticeable increase in the growth index and valuation index. Earnings per share increased from -$0.0358 to -$0.0305, EBIT increased 11.92% from -$6.66M to -$5.87M, and operating cash flow increased 10.5% from -$5.78M to -$5.18M.
E
Sell
7/31/2024Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to E+ from D- on 7/31/2024 due to a decline in the volatility index, total return index and valuation index.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to E+ from D- on 7/31/2024 due to a decline in the volatility index, total return index and valuation index.
D
Sell
7/11/2024Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D- from E+ on 7/11/2024 due to an increase in the volatility index.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D- from E+ on 7/11/2024 due to an increase in the volatility index.
E
Sell
6/25/2024Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to E+ from D- on 6/25/2024 due to a decline in the total return index and volatility index.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to E+ from D- on 6/25/2024 due to a decline in the total return index and volatility index.
D
Sell
6/3/2024Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D- from E+ on 6/3/2024 due to an increase in the volatility index and valuation index.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D- from E+ on 6/3/2024 due to an increase in the volatility index and valuation index.
E
Sell
5/17/2024Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to E+ from D- on 5/17/2024 due to a noticeable decline in the growth index, volatility index and total return index. EBIT declined 135.2% from -$2.83M to -$6.66M, earnings per share declined from -$0.0273 to -$0.0358, and total revenue declined 30.84% from $2.09M to $1.44M.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to E+ from D- on 5/17/2024 due to a noticeable decline in the growth index, volatility index and total return index. EBIT declined 135.2% from -$2.83M to -$6.66M, earnings per share declined from -$0.0273 to -$0.0358, and total revenue declined 30.84% from $2.09M to $1.44M.
D
Sell
4/29/2024Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D- from E+ on 4/29/2024 due to an increase in the volatility index, total return index and valuation index.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D- from E+ on 4/29/2024 due to an increase in the volatility index, total return index and valuation index.
E
Sell
3/25/2024Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to E+ from D- on 3/25/2024 due to a decline in the volatility index and valuation index.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to E+ from D- on 3/25/2024 due to a decline in the volatility index and valuation index.
D
Sell
3/8/2024Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D- from E+ on 3/8/2024 due to a noticeable increase in the growth index, volatility index and total return index. Total revenue increased 67.58% from $1.25M to $2.09M, EBIT increased 57.76% from -$6.71M to -$2.83M, and earnings per share increased from -$0.0407 to -$0.0273.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D- from E+ on 3/8/2024 due to a noticeable increase in the growth index, volatility index and total return index. Total revenue increased 67.58% from $1.25M to $2.09M, EBIT increased 57.76% from -$6.71M to -$2.83M, and earnings per share increased from -$0.0407 to -$0.0273.
E
Sell
2/26/2024Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to E+ from D- on 2/26/2024 due to a decline in the volatility index, total return index and valuation index.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to E+ from D- on 2/26/2024 due to a decline in the volatility index, total return index and valuation index.
D
Sell
2/8/2024Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D- from E+ on 2/8/2024 due to an increase in the volatility index and valuation index.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D- from E+ on 2/8/2024 due to an increase in the volatility index and valuation index.
E
Sell
1/23/2024Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to E+ from D- on 1/23/2024 due to a noticeable decline in the volatility index, total return index and growth index. Total revenue declined 61.36% from $3.23M to $1.25M, EBIT declined 33.46% from -$5.02M to -$6.71M, and earnings per share declined from -$0.0307 to -$0.0407.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to E+ from D- on 1/23/2024 due to a noticeable decline in the volatility index, total return index and growth index. Total revenue declined 61.36% from $3.23M to $1.25M, EBIT declined 33.46% from -$5.02M to -$6.71M, and earnings per share declined from -$0.0307 to -$0.0407.
D
Sell
3/14/2023Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D- from D+ on 3/14/2023 due to a decline in the valuation index.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D- from D+ on 3/14/2023 due to a decline in the valuation index.
D
Sell
3/10/2023Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D+ from D on 3/10/2023 due to a large increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.04 to -$0.0374, and the quick ratio increased from 2.94 to 3.06.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D+ from D on 3/10/2023 due to a large increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.04 to -$0.0374, and the quick ratio increased from 2.94 to 3.06.
D
Sell
2/23/2023Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index and valuation index.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index and valuation index.
D
Sell
2/8/2023Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index, solvency index and valuation index.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index, solvency index and valuation index.
D
Sell
5/31/2022Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D from D- on 5/31/2022 due to an increase in the total return index and volatility index.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D from D- on 5/31/2022 due to an increase in the total return index and volatility index.
D
Sell
5/13/2022Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D- from D on 5/13/2022 due to a decline in the solvency index and total return index.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D- from D on 5/13/2022 due to a decline in the solvency index and total return index.
D
Sell
5/5/2022Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index and growth index.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index and growth index.
D
Sell
4/20/2022Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D- from D on 4/20/2022 due to a decline in the volatility index.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D- from D on 4/20/2022 due to a decline in the volatility index.
D
Sell
3/15/2022Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D from D+ on 3/15/2022 due to a substantial decline in the growth index, solvency index and total return index. EBIT declined 312.66% from -$6.84M to -$28.24M, earnings per share declined from -$0.05 to -$0.1719, and the quick ratio declined from 7.62 to 2.32.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D from D+ on 3/15/2022 due to a substantial decline in the growth index, solvency index and total return index. EBIT declined 312.66% from -$6.84M to -$28.24M, earnings per share declined from -$0.05 to -$0.1719, and the quick ratio declined from 7.62 to 2.32.
D
Sell
1/7/2022Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D+ from D on 1/7/2022 due to an increase in the volatility index.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D+ from D on 1/7/2022 due to an increase in the volatility index.
D
Sell
12/23/2021Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D from D+ on 12/23/2021 due to a decline in the volatility index and total return index.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D from D+ on 12/23/2021 due to a decline in the volatility index and total return index.
D
Sell
11/26/2021Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D+ from D on 11/26/2021 due to an increase in the valuation index.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D+ from D on 11/26/2021 due to an increase in the valuation index.
D
Sell
11/11/2021Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D from D+ on 11/11/2021 due to a decline in the solvency index and valuation index. The quick ratio declined from 10.21 to 7.41.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D from D+ on 11/11/2021 due to a decline in the solvency index and valuation index. The quick ratio declined from 10.21 to 7.41.
D
Sell
11/9/2021Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D+ from D- on 11/09/2021.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D+ from D- on 11/09/2021.
D
Sell
11/8/2021Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D- from D+ on 11/08/2021.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D- from D+ on 11/08/2021.
D
Sell
10/22/2021Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D+ from D on 10/22/2021 due to an increase in the valuation index.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D+ from D on 10/22/2021 due to an increase in the valuation index.
D
Sell
10/6/2021Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D from D+ on 10/6/2021 due to a decline in the valuation index.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D from D+ on 10/6/2021 due to a decline in the valuation index.
D
Sell
8/27/2021Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D+ from D on 8/27/2021 due to an increase in the solvency index, growth index and valuation index. Total revenue increased 30.95% from $391 to $512, operating cash flow increased 27.05% from -$7.42M to -$5.42M, and the quick ratio increased from 9.44 to 10.21.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D+ from D on 8/27/2021 due to an increase in the solvency index, growth index and valuation index. Total revenue increased 30.95% from $391 to $512, operating cash flow increased 27.05% from -$7.42M to -$5.42M, and the quick ratio increased from 9.44 to 10.21.
D
Sell
6/16/2021Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D from D+ on 6/16/2021 due to a decline in the valuation index.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D from D+ on 6/16/2021 due to a decline in the valuation index.
D
Sell
6/1/2021Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D+ from D on 6/1/2021 due to an increase in the solvency index, volatility index and total return index. The quick ratio increased from 5.41 to 9.44.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D+ from D on 6/1/2021 due to an increase in the solvency index, volatility index and total return index. The quick ratio increased from 5.41 to 9.44.
D
Sell
3/29/2021Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D from D+ on 3/29/2021 due to a decline in the valuation index.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D from D+ on 3/29/2021 due to a decline in the valuation index.
D
Sell
3/12/2021Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D+ from D on 3/12/2021 due to a large increase in the solvency index, total return index and volatility index. The quick ratio increased from 4.94 to 5.41.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D+ from D on 3/12/2021 due to a large increase in the solvency index, total return index and volatility index. The quick ratio increased from 4.94 to 5.41.
D
Sell
1/19/2021Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D from D+ on 1/19/2021 due to a decline in the valuation index.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D from D+ on 1/19/2021 due to a decline in the valuation index.
D
Sell
11/9/2020Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D+ from D on 11/9/2020 due to a large increase in the total return index, volatility index and growth index. Total revenue increased 47.93% from $386 to $571.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D+ from D on 11/9/2020 due to a large increase in the total return index, volatility index and growth index. Total revenue increased 47.93% from $386 to $571.
D
Sell
2/6/2020Upgraded
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D from D- on 2/6/2020 due to an increase in the volatility index.
Lineage Cell Therapeutics, Inc. (LCTX) was upgraded to D from D- on 2/6/2020 due to an increase in the volatility index.
D
Sell
12/10/2019Downgrade
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D- from D on 12/10/2019 due to a noticeable decline in the solvency index, volatility index and efficiency index. Total capital declined 11.57% from $136.63M to $120.83M.
Lineage Cell Therapeutics, Inc. (LCTX) was downgraded to D- from D on 12/10/2019 due to a noticeable decline in the solvency index, volatility index and efficiency index. Total capital declined 11.57% from $136.63M to $120.83M.
D
Sell
4/17/2019Upgraded
BioTime, Inc. (BTX) was upgraded to D from D- on 4/17/2019 due to an increase in the total return index and volatility index.
BioTime, Inc. (BTX) was upgraded to D from D- on 4/17/2019 due to an increase in the total return index and volatility index.
D
Sell
3/29/2019Downgrade
BioTime, Inc. (BTX) was downgraded to D- from D on 3/29/2019 due to a decline in the total return index, efficiency index and solvency index. Net income declined 167.37% from $66.73M to -$44.95M, total capital declined 44.79% from $171.19M to $94.51M, and the quick ratio declined from 7.8 to 5.06.
BioTime, Inc. (BTX) was downgraded to D- from D on 3/29/2019 due to a decline in the total return index, efficiency index and solvency index. Net income declined 167.37% from $66.73M to -$44.95M, total capital declined 44.79% from $171.19M to $94.51M, and the quick ratio declined from 7.8 to 5.06.
D
Sell
11/14/2018Upgraded
BioTime, Inc. (BTX) was upgraded to D from D- on 11/14/2018 due to a large increase in the efficiency index, growth index and solvency index. Earnings per share increased from -$0.0332 to $0.5259, net income increased 1,683.04% from -$4.22M to $66.73M, and total capital increased 61.31% from $106.13M to $171.19M.
BioTime, Inc. (BTX) was upgraded to D from D- on 11/14/2018 due to a large increase in the efficiency index, growth index and solvency index. Earnings per share increased from -$0.0332 to $0.5259, net income increased 1,683.04% from -$4.22M to $66.73M, and total capital increased 61.31% from $106.13M to $171.19M.
D
Sell
5/11/2018Downgrade
BioTime, Inc. (BTX) was downgraded to D- from D on 5/11/2018 due to a noticeable decline in the efficiency index, growth index and solvency index. Operating cash flow declined 82.17% from -$5.68M to -$10.34M, total capital declined 37.34% from $165.8M to $103.89M, and total revenue declined 29.83% from $999 to $701.
BioTime, Inc. (BTX) was downgraded to D- from D on 5/11/2018 due to a noticeable decline in the efficiency index, growth index and solvency index. Operating cash flow declined 82.17% from -$5.68M to -$10.34M, total capital declined 37.34% from $165.8M to $103.89M, and total revenue declined 29.83% from $999 to $701.
D
Sell
3/16/2018Downgrade
BioTime, Inc. (BTX) was downgraded to D from D+ on 3/16/2018 due to a significant decline in the valuation index, growth index and efficiency index. Net income declined 602.3% from $14.32M to -$71.93M, earnings per share declined from $0.12 to -$0.5763, and total revenue declined 40.82% from $1.69M to $999.
BioTime, Inc. (BTX) was downgraded to D from D+ on 3/16/2018 due to a significant decline in the valuation index, growth index and efficiency index. Net income declined 602.3% from $14.32M to -$71.93M, earnings per share declined from $0.12 to -$0.5763, and total revenue declined 40.82% from $1.69M to $999.
D
Sell
11/13/2017Upgraded
BioTime, Inc. (BTX) was upgraded to D+ from D on 11/13/2017 due to a substantial increase in the growth index, solvency index and valuation index. Total revenue increased 343.04% from $381 to $1.69M, earnings per share increased from -$0.11 to $0.12, and the quick ratio increased from 1.39 to 3.64.
BioTime, Inc. (BTX) was upgraded to D+ from D on 11/13/2017 due to a substantial increase in the growth index, solvency index and valuation index. Total revenue increased 343.04% from $381 to $1.69M, earnings per share increased from -$0.11 to $0.12, and the quick ratio increased from 1.39 to 3.64.
D
Sell
9/11/2017Downgrade
BioTime, Inc. (BTX) was downgraded to D from D+ on 9/11/2017 due to a noticeable decline in the growth index, total return index and solvency index. Earnings per share declined from $0.46 to -$0.11, debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 3.15 to 1.39.
BioTime, Inc. (BTX) was downgraded to D from D+ on 9/11/2017 due to a noticeable decline in the growth index, total return index and solvency index. Earnings per share declined from $0.46 to -$0.11, debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 3.15 to 1.39.
D
Sell
7/27/2017Downgrade
BioTime, Inc. (BTX) was downgraded to D+ from C- on 7/27/2017 due to a decline in the volatility index and total return index.
BioTime, Inc. (BTX) was downgraded to D+ from C- on 7/27/2017 due to a decline in the volatility index and total return index.
C
Hold
7/12/2017Upgraded
BioTime, Inc. (BTX) was upgraded to C- from D+ on 7/12/2017 due to an increase in the volatility index and total return index.
BioTime, Inc. (BTX) was upgraded to C- from D+ on 7/12/2017 due to an increase in the volatility index and total return index.
D
Sell
6/27/2017Downgrade
BioTime, Inc. (BTX) was downgraded to D+ from C- on 6/27/2017 due to a decline in the volatility index.
BioTime, Inc. (BTX) was downgraded to D+ from C- on 6/27/2017 due to a decline in the volatility index.
C
Hold
5/11/2017Upgraded
BioTime, Inc. (BTX) was upgraded to C- from D+ on 5/11/2017 due to a noticeable increase in the valuation index, growth index and total return index. Earnings per share increased from -$0.0494 to $0.46, and operating cash flow increased 8.52% from -$8.85M to -$8.1M.
BioTime, Inc. (BTX) was upgraded to C- from D+ on 5/11/2017 due to a noticeable increase in the valuation index, growth index and total return index. Earnings per share increased from -$0.0494 to $0.46, and operating cash flow increased 8.52% from -$8.85M to -$8.1M.
D
Sell
3/21/2017Downgrade
BioTime, Inc. (BTX) was downgraded to D+ from C- on 3/21/2017 due to a noticeable decline in the growth index, solvency index and efficiency index. Earnings per share declined from $0.3 to -$0.0494, net income declined 116.27% from $31.2M to -$5.08M, and debt to equity increased from 0.01 to 0.02.
BioTime, Inc. (BTX) was downgraded to D+ from C- on 3/21/2017 due to a noticeable decline in the growth index, solvency index and efficiency index. Earnings per share declined from $0.3 to -$0.0494, net income declined 116.27% from $31.2M to -$5.08M, and debt to equity increased from 0.01 to 0.02.
C
Hold
2/3/2017Upgraded
BioTime, Inc. (BTX) was upgraded to C- from D+ on 2/3/2017 due to an increase in the total return index, valuation index and volatility index.
BioTime, Inc. (BTX) was upgraded to C- from D+ on 2/3/2017 due to an increase in the total return index, valuation index and volatility index.
D
Sell
1/19/2017Downgrade
BioTime, Inc. (BTX) was downgraded to D+ from C- on 1/19/2017 due to a decline in the total return index and valuation index.
BioTime, Inc. (BTX) was downgraded to D+ from C- on 1/19/2017 due to a decline in the total return index and valuation index.
C
Hold
11/8/2016Upgraded
BioTime, Inc. (BTX) was upgraded to C- from D on 11/8/2016 due to a significant increase in the valuation index, efficiency index and solvency index. Total capital increased 44.19% from $96.7M to $139.43M, net income increased 27.09% from $24.55M to $31.2M, and the quick ratio increased from 3.95 to 3.97.
BioTime, Inc. (BTX) was upgraded to C- from D on 11/8/2016 due to a significant increase in the valuation index, efficiency index and solvency index. Total capital increased 44.19% from $96.7M to $139.43M, net income increased 27.09% from $24.55M to $31.2M, and the quick ratio increased from 3.95 to 3.97.
D
Sell
8/10/2016Upgraded
BioTime, Inc. (BTX) was upgraded to D from D- on 8/10/2016 due to an increase in the total return index, growth index and valuation index. Earnings per share increased from -$0.1892 to $0.26, EBIT increased 39.38% from -$23.76M to -$14.4M, and operating cash flow increased 28.41% from -$14.31M to -$10.25M.
BioTime, Inc. (BTX) was upgraded to D from D- on 8/10/2016 due to an increase in the total return index, growth index and valuation index. Earnings per share increased from -$0.1892 to $0.26, EBIT increased 39.38% from -$23.76M to -$14.4M, and operating cash flow increased 28.41% from -$14.31M to -$10.25M.
D
Sell
3/11/2016Downgrade
BioTime, Inc. (BTX) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index. Debt to equity increased from 0.02 to 0.05, and the quick ratio declined from 3.83 to 3.08.
BioTime, Inc. (BTX) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index. Debt to equity increased from 0.02 to 0.05, and the quick ratio declined from 3.83 to 3.08.
AMEX
03/17/2025 4:00PM Eastern
Quotes delayed
